Cupid Limited Set to Deliver Best-Ever Quarter, Beating FY26 Guidance
Cupid Limited is positioned to achieve record quarterly results while exceeding its FY26 financial guidance of ₹335 Cr revenue and ₹100 Cr net profit. The company has set ambitious FY27 targets of at least ₹600 Cr revenue with profit margins above 30%, supported by strong export growth, favorable currency conditions, and secured raw material inventory.

*this image is generated using AI for illustrative purposes only.
Cupid Limited is positioned to deliver its best-ever quarterly performance while surpassing its FY26 guidance, demonstrating exceptional execution across its core business segments. The Mumbai-based manufacturer and exporter of male condoms, female condoms, water-based lubricants, and IVD kits has confirmed strong performance that will exceed the company's annual revenue guidance of ₹335 Cr and net profit guidance of ₹100 Cr for FY26.
Record Quarterly Performance Against Annual Targets
The company's robust operational execution has positioned it to deliver its strongest quarterly results while comfortably exceeding established financial guidance for the current fiscal year.
| Performance Metric: | FY26 Guidance | Status |
|---|---|---|
| Revenue: | ₹335 Cr | Set to Surpass |
| Net Profit: | ₹100 Cr | Set to Surpass |
| Quarterly Performance: | - | Best-Ever Quarter |
This exceptional performance reflects the company's effective business model execution and sustained demand momentum across its diverse product portfolio.
Ambitious Growth Targets for FY27
Building on this strong foundation, Cupid Limited has outlined ambitious targets for the upcoming fiscal year, reflecting confidence in its growth trajectory.
| FY27 Targets: | Projections |
|---|---|
| Revenue: | At least ₹600 Cr |
| Net Profit Margin: | In excess of 30% |
These targets represent significant growth expectations, supported by the company's expanding market presence and operational capabilities.
Strategic Advantages Supporting Growth
The company operates from a position of considerable strength, with multiple factors supporting its growth outlook:
- Raw Material Security: Adequate inventory ensuring no near-term challenges from crude-derived inputs, with visibility secured for the next six months
- Currency Benefits: Favorable USD-INR environment supporting export realizations
- Export Expansion: Strong growth outlook with increasing traction across international markets
Management Commentary
Mr. Aditya Kumar Halwasiya, Chairman & Managing Director, expressed satisfaction with the record performance trajectory: "We are pleased with our performance that is set to exceed our annual guidance on both revenue and profitability. This reflects the strength of our business model, disciplined execution, and growing global demand for our products."
He further emphasized the company's growth prospects: "Looking ahead, we are confident of sustaining this growth momentum. With strong export tailwinds, stable input costs, and a well-secured raw material position, we are well positioned to scale our operations meaningfully over the coming years."
Company Profile and Market Position
Established in 1993, Cupid Limited has evolved into India's premier manufacturer of male and female condoms, water-based personal lubricants, IVD kits, and various FMCG products including deodorants, perfumes, and personal care items. The company holds the distinction of being the first globally to attain WHO/UNFPA pre-qualification for both male and female condoms.
The company's international presence spans over 125 countries, with substantial revenue generated from export markets. Recent strategic initiatives include a land acquisition in Palava, Maharashtra, which will amplify production capacity by 1.5 times, adding approximately 770 million male condoms and 75 million female condoms to annual capacity.
Historical Stock Returns for Cupid
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.27% | +18.90% | +38.09% | +118.10% | +652.36% | +938.94% |
How will the new Palava facility's 1.5x capacity expansion impact Cupid's ability to capture additional market share in the 125+ countries it serves?
What specific strategies will Cupid employ to maintain its 30%+ net profit margin target amid potential raw material price volatility beyond the secured six-month period?
Could Cupid's strong export performance and WHO/UNFPA pre-qualification status position it for larger institutional contracts with global health organizations?


































